To the Editors: The SARS-CoV-2 pandemic has affected research efforts worldwide. Previously, we described our strategy to mitigate COVID-19 transmission risk during an ongoing HIV cure-related clinical trial. SARS-CoV-2 vaccines recently have been authorized for emergency use and will become available to people with HIV imminently. As a result, researchers must determine how to adjust study protocols to incorporate the likelihood that participants may be vaccinated
